Journal Article

18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non–small cell lung cancer: a systematic review and meta-analysis

Zanon Matheus, de Souza Santos Francisco, Henz Concatto Natália, Tan-Lucien, Mohammed, Mattiello Rita, Machado Medeiros Tássia, Altmayer, Stephan, Verma Nupur, Basso Dias Adriano, Hoefel Paes Julia, Watte Guilherme, Hochhegger Bruno

2020

Overview

ObjectivesTo evaluate the diagnostic test accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), whole-body magnetic resonance imaging (WB-MRI), and whole-body diffusion-weighted imaging (WB-DWI) for the detection of metastases in patients with non–small cell lung cancer (NSCLC).MethodsMEDLINE, Embase, and Cochrane Library databases were searched up to June 2019. Studies were selected if they reported data that could be used to construct contingency tables to compare 18F-FDG PET/CT, WB-MRI, and WB-DWI. Two authors independently extracted data on study characteristics and assessed methodological quality using the Quality Assessment of Diagnostic Accuracy Studies. Forest plots were generated for sensitivity and specificity of 18F-FDG PET/CT, WB-MRI, and whole-body diffusion-weighted imaging (WB-DWI). Summary receiver operating characteristic plots were created.ResultsThe 4 studies meeting inclusion criteria had a total of 564 patients and 559 lesions, 233 of which were metastases. In studies of 18F-FDG PET/CT, the pooled estimates of sensitivity and specificity were 0.83 (95% confidence interval [CI], 0.54–0.95) and 0.93 (95% CI, 0.87–0.96), respectively. For WB-MRI, pooled sensitivity was 0.92 (95% CI, 0.18–1.00) and pooled specificity was 0.93 (95% CI, 0.85–0.95). Pooled sensitivity and specificity for WB-DWI were 0.78 (95% CI, 0.46–0.93) and 0.91 (95% CI, 0.79–0.96), respectively. There was no statistical difference between the diagnostic odds ratio of WB-MRI and WB-DWI compared with that of PET/CT (p = 0.186 for WB-DWI; p = 0.638 for WB-MRI).ConclusionWB-MRI and DWI are radiation-free alternatives with comparable diagnostic performance to 18F-FDG PET/CT for M staging of NSCLC.Key Points• Whole-body MRI with or without diffusion-weighted imaging has a high accuracy for the diagnostic evaluation of metastases in patients with non–small cell lung cancer.• Whole-body MRI may be used as a non-invasive and radiation-free alternative to positron emission tomography with CT with similar diagnostic performance.

• Publisher: Springer Nature B.V
• Subject: Accuracy / Computed tomography / Confidence intervals / Contingency / Diagnostic systems / Diffusion / Emission analysis / Fluorine isotopes / Lung cancer / Magnetic resonance imaging / Medical diagnosis / Medical imaging / Meta-analysis / Metastases / Metastasis / Non-small cell lung carcinoma / Positron emission / Positron emission tomography / Quality assessment / Quality control / Radiation / Small cell lung carcinoma / Statistical analysis / Tomography